Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Kwong Wah Hospital | OTHER |
| Princess Margaret Hospital, Hong Kong | OTHER_GOV |
| Pamela Youde Nethersole Eastern Hospital | OTHER |
| The Queen Elizabeth Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
This is a randomized double-blind controlled trial on the effect of vitamin D supplementation to assess the ovulation rate of women with polycystic ovary syndrome (PCOS) and other reproductive, endocrine and metabolic outcomes after one year of treatment.
The hypothesis is that vitamin D supplementation results in significant improvement in the ovulation rate of women with PCOS either spontaneously or with oral ovulation induction agent.
Anovulatory women with PCOS diagnosed by the Rotterdam criteria will be recruited.
Participants will be randomized to the (1) vitamin D group or (2) placebo group. Those in the vitamin D group will take vitamin D 50,000 IU/ week for 4 weeks, followed by 50,000IU once every 2 weeks for 52 weeks, whereas those in the placebo group will take placebo tablets with the same external appearance. Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction.
The primary outcome is the ovulation rate and will be compared between the 2 groups.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Vitamin D | Active Comparator | Vitamin D 50,000 IU/ week for 4 weeks, followed by 50,000 IU once every 2 weeks for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction. |
|
| Placebo | Placebo Comparator | Placebo tablets with same external appearance for 52 weeks Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5mg to 7.5mg for 5 days per cycle titrated according to response) for ovulation induction. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vitamin D | Dietary Supplement | Vitamin D supplementation |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Ovulation rate | Serum progesterone | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in serum 25(OH)D level | Serum 25(OH)D | 12 months |
| Pregnancy rate | Positive urine or serum hCG test | 12 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
For those on supplements, we asked them to stop their own supplements.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kwong Wah Hospital | Recruiting | Hong Kong | Hong Kong |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38684265 | Derived | Ko JKY, Yung SSF, Lai SF, Wan RSF, Wong CKY, Wong K, Cheung CL, Ng EHY, Li RHW. Effect of vitamin D in addition to letrozole on the ovulation rate of women with polycystic ovary syndrome: protocol of a multicentre randomised double-blind controlled trial. BMJ Open. 2024 Apr 29;14(4):e070801. doi: 10.1136/bmjopen-2022-070801. |
Not provided
Not provided
all IPD that underlie results in a publication
Not provided
starting 6 months after publication
review by investigators
Not provided
Not provided
| ID | Term |
|---|---|
| D011085 | Polycystic Ovary Syndrome |
| D000858 | Anovulation |
| ID | Term |
|---|---|
| D010048 | Ovarian Cysts |
| D003560 | Cysts |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 |
Not provided
Not provided
| ID | Term |
|---|---|
| D014807 | Vitamin D |
| ID | Term |
|---|---|
| D012632 | Secosteroids |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Not provided
| Other |
Placebo tablets with the same external appearance |
|
| Live birth rate | Delivery of a baby after 22 completed weeks of gestational age, or with birth weight of 500 grams if the gestation age is unknown, which shows evidence of life | 12 months |
| Change in serum anti-Mullerian hormone level | serum AMH level | 12 months |
| Change in antral follicle count | Antral follicle count measured by transvaginal/ transrectal ultrasound | 12 months |
| Androgen indices | serum androgen and androstenedione levels, SHBG | 12 months |
| Body mass index | Height in cm, weight in kg, to calculate the body mass index (kg/m^2) | 12 months |
| Change in waist and hip circumference | waist and hip circumference in cm | 12 months |
| Rate of diabetes mellitus/ impaired glucose intolerance | Measured by fasting and 2 hour glucose (post 75g OGTT) | 12 months |
| Change in systolic and diastolic blood pressure | Blood pressure | 12 months |
| Princess Margaret Hospital | Not yet recruiting | Hong Kong | Hong Kong |
|
| Queen Mary Hospital, University of Hong Kong | Recruiting | Hong Kong | Hong Kong |
|
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |